MLV glycosylated-gag is an infectivity factor that rescues Nef-deficient HIV-1

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 20, 2010, Pages 9364-9369

  Pizzato, Massimo ^a,b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GAG PROTEIN; NEF PROTEIN; VIRULENCE FACTOR; VIRUS DNA; VIRUS ENVELOPE PROTEIN;

ARTICLE; CONTROLLED STUDY; DELETION MUTANT; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPHOID CELL; MURINE LEUKEMIA VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; VIRION;

BLOTTING, WESTERN; DNA PRIMERS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; EVOLUTION, MOLECULAR; GENE PRODUCTS, GAG; GLYCOSYLATION; HIV-1; LEUKEMIA VIRUS, MURINE; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

HUMAN IMMUNODEFICIENCY VIRUS 1; MURINE LEUKEMIA VIRUS;

EID: 77952683763     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1001554107     Document Type: Article

References (68)

1. Kestler HW, 3rd, et al. (1991) Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65:651-662.
2. Deacon NJ, et al. (1995) Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 270:988-991.
3. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC (1995) Brief report: Absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med 332:228-232.
4. Garcia JV, Miller AD (1991) Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature 350:508-511.
5. Aiken C, Konner J, Landau NR, Lenburg ME, Trono D (1994) Nef induces CD4 endocytosis: Requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell 76:853-864.
6. Schwartz O, Maréchal V, Le Gall S, Lemonnier F, Heard JM (1996) Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med 2:338-342.
7. Bell I, et al. (1998) Association of simian immunodeficiency virus Nef with the T-cell receptor (TCR) zeta chain leads to TCR down-modulation. J Gen Virol 79:2717-2727.
8. Münch J, et al. (2002) T-cell receptor:CD3 down-regulation is a selected in vivo function of simian immunodeficiency virus Nef but is not sufficient for effective viral replication in rhesus macaques. J Virol 76:12360-12364.
9. Schindler M, et al. (2006) Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell 125:1055-1067.
10. Baur AS, et al. (1994) HIV-1 Nef leads to inhibition or activation of T cells depending on its intracellular localization. Immunity 1:373-384.
11. Schrager JA, Marsh JW (1999) HIV-1 Nef increases T cell activation in a stimulus-dependent manner. Proc Natl Acad Sci USA 96:8167-8172.
12. Simmons A, Aluvihare V, McMichael A (2001) Nef triggers a transcriptional program in T cells imitating single-signal T cell activation and inducing HIV virulence mediators. Immunity 14:763-777.
13. Saksela K, Cheng G, Baltimore D (1995) Proline-rich (PxxP) motifs in HIV-1 Nef bind to SH3 domains of a subset of Src kinases and are required for the enhanced growth of Nef+ viruses but not for down-regulation of CD4. EMBO J 14:484-491.
14. Renkema GH, Manninen A, Mann DA, Harris M, Saksela K (1999) Identification of the Nef-associated kinase as p21-activated kinase 2. Curr Biol 9:1407-1410.
15. Sawai ET, et al. (1994) Human immunodeficiency virus type 1 Nef associates with a cellular serine kinase in T lymphocytes. Proc Natl Acad Sci USA 91:1539-1543.
16. Fackler OT, Luo W, Geyer M, Alberts AS, Peterlin BM (1999) Activation of Vav by Nef induces cytoskeletal rearrangements and downstream effector functions. Mol Cell 3: 729-739.
17. Geleziunas R, Xu W, Takeda K, Ichijo H, Greene WC (2001) HIV-1 Nef inhibits ASK1-dependent death signalling providing a potential mechanism for protecting the infected host cell. Nature 410:834-838.
18. Chowers MY, et al. (1994) Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef gene. J Virol 68:2906-2914.
19. Miller MD, Warmerdam MT, Gaston I, Greene WC, Feinberg MB (1994) The human immunodeficiency virus-1 nef gene product: A positive factor for viral infection and replication in primary lymphocytes and macrophages. J Exp Med 179:101-113.
20. Lama J, Mangasarian A, Trono D (1999) Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-inhibitable manner. Curr Biol 9:622-631.
21. Chowers MY, Pandori MW, Spina CA, Richman DD, Guatelli JC (1995) The growth advantage conferred by HIV-1 nef is determined at the level of viral DNA formation and is independent of CD4 downregulation. Virology 212:451-457.
22. Aiken C, Trono D (1995) Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J Virol 69:5048-5056.
23. Goldsmith MA, Warmerdam MT, Atchison RE, Miller MD, Greene WC (1995) Dissociation of the CD4 downregulation and viral infectivity enhancement functions of human immunodeficiency virus type 1 Nef. J Virol 69:4112-4121.
24. Pandori MW, et al. (1996) Producer-cell modification of human immunodeficiency virus type 1: Nef is a virion protein. J Virol 70:4283-4290.
25. Schwartz O, Maréchal V, Danos O, Heard JM (1995) Human immunodeficiency virus type 1 Nef increases the efficiency of reverse transcription in the infected cell. J Virol 69:4053-4059.
26. Cavrois M, Neidleman J, Yonemoto W, Fenard D, Greene WC (2004) HIV-1 virion fusion assay: Uncoating not required and no effect of Nef on fusion. Virology 328: 36-44.
27. Campbell EM, Nunez R, Hope TJ (2004) Disruption of the actin cytoskeleton can complement the ability of Nef to enhance human immunodeficiency virus type 1 infectivity. J Virol 78:5745-5755.
28. Aiken C (1997) Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J Virol 71:5871-5877.
29. Chazal N, Singer G, Aiken C, Hammarskjöld ML, Rekosh D (2001) Human immunodeficiency virus type 1 particles pseudotyped with envelope proteins that fuse at low pH no longer require Nef for optimal infectivity. J Virol 75:4014-4018.
30. Fackler OT, et al. (2006) Functional characterization of HIV-1 Nef mutants in the context of viral infection. Virology 351:322-339.
31. Laguette N, Benichou S, Basmaciogullari S (2009) Human immunodeficiency virus type 1 Nef incorporation into virions does not increase infectivity. J Virol 83:1093-1104.
32. Pizzato M, et al. (2007) Dynamin 2 is required for the enhancement of HIV-1 infectivity by Nef. Proc Natl Acad Sci USA 104:6812-6817.
33. Bresnahan PA, et al. (1998) A dileucine motif in HIV-1 Nef acts as an internalization signal for CD4 downregulation and binds the AP-1 clathrin adaptor. Curr Biol 8: 1235-1238.
34. Craig HM, Pandori MW, Guatelli JC (1998) Interaction of HIV-1 Nef with the cellular dileucine-based sorting pathway is required for CD4 down-regulation and optimal viral infectivity. Proc Natl Acad Sci USA 95:11229-11234.
35. Edwards SA, Fan H (1979) gag-Related polyproteins of Moloney murine leukemia virus: Evidence for independent synthesis of glycosylated and unglycosylated forms. J Virol 30:551-563.
36. Evans LH, Dresler S, Kabat D (1977) Synthesis and glycosylation of polyprotein precursors to the internal core proteins of Friend murine leukemia virus. J Virol 24: 865-874.
37. Neil JC, Smart JE, Hayman MJ, Jarrett O (1980) Polypeptides of feline leukemia virus: A glycosylated gag-related protein is released into culture fluids. Virology 105:250-253.
38. Schultz AM, Rabin EH, Oroszlan S (1979) Post-translational modification of Rauscher leukemia virus precursor polyproteins encoded by the gag gene. J Virol 30:255-266.
39. Prats AC, De Billy G, Wang P, Darlix JL (1989) CUG initiation codon used for the synthesis of a cell surface antigen coded by the murine leukemia virus. J Mol Biol 205: 363-372.
40. Fujisawa R, McAtee FJ, Zirbel JH, Portis JL (1997) Characterization of glycosylated Gag expressed by a neurovirulent murine leukemia virus: Identification of differences in processing in vitro and in vivo. J Virol 71:5355-5360.
41. Schwartzberg P, Colicelli J, Goff SP (1983) Deletion mutants of Moloney murine leukemia virus which lack glycosylated gag protein are replication competent. J Virol 46:538-546.
42. Goff SP, Lobel LI (1987) Mutants of murine leukemia viruses and retroviral replication. Biochim Biophys Acta 907:93-123.
43. Chun R, Fan H (1994) Recovery of glycosylated gag virus from mice infected with a glycosylated gag-negative mutant of Moloney murine leukemia virus. J Biomed Sci 1:218-223.
44. Fan H, Chute H, Chao E, Feuerman M (1983) Construction and characterization of Moloney murine leukemia virus mutants unable to synthesize glycosylated gag polyprotein. Proc Natl Acad Sci USA 80:5965-5969.
45. Corbin A, Prats AC, Darlix JL, Sitbon M (1994) A nonstructural gag-encoded glycoprotein precursor is necessary for efficient spreading and pathogenesis of murine leukemia viruses. J Virol 68:3857-3867.
46. Fujisawa R, McAtee FJ, Wehrly K, Portis JL (1998) The neuroinvasiveness of a murine retrovirus is influenced by a dileucine-containing sequence in the cytoplasmic tail of glycosylated Gag. J Virol 72:5619-5625.
47. Münk C, et al. (2003) 10A1-MuLV but not the related amphotropic 4070A MuLV is highly neurovirulent: Importance of sequences upstream of the structural Gag coding region. Virology 313:44-55.
48. Nitta T, Kuznetsov Y, McPherson A, Fan H (2010) Murine leukemia virus glycosylated Gag (gPr80gag) facilitates interferon-sensitive virus release through lipid rafts. Proc Natl Acad Sci USA 107:1190-1195.
49. Takeuchi Y, McClure MO, Pizzato M (2008) Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. J Virol 82:12585-12588.
50. Raisch KP, et al. (2003) Molecular cloning, complete sequence, and biological characterization of a xenotropic murine leukemia virus constitutively released from the human B-lymphoblastoid cell line DG-75. Virology 308:83-91.
51. Pizzato M, et al. (2009) A one-step SYBR Green I-based product-enhanced reverse transcriptase assay for the quantitation of retroviruses in cell culture supernatants. J Virol Methods 156:1-7.
52. Kizhatil K, Albritton LM (1997) Requirements for different components of the host cell cytoskeleton distinguish ecotropic murine leukemia virus entry via endocytosis from entry via surface fusion. J Virol 71:7145-7156.
53. McClure MO, Sommerfelt MA, Marsh M, Weiss RA (1990) The pH independence of mammalian retrovirus infection. J Gen Virol 71:767-773.
54. Tsukahara T, Ratner L (2004) Substitution of HIV Type 1 Nef with HTLV-1 p12. AIDS Res Hum Retroviruses 20:938-943.
55. Greenberg M, DeTulleo L, Rapoport I, Skowronski J, Kirchhausen T (1998) A dileucine motif in HIV-1 Nef is essential for sorting into clathrin-coated pits and for downregulation of CD4. Curr Biol 8:1239-1242.
56. Greenberg ME, Iafrate AJ, Skowronski J (1998) The SH3 domain-binding surface and an acidic motif in HIV-1 Nef regulate trafficking of class I MHC complexes. EMBO J 17: 2777-2789.
57. Tobiume M, Lineberger JE, Lundquist CA, Miller MD, Aiken C (2003) Nef does not affect the efficiency of human immunodeficiency virus type 1 fusion with target cells. J Virol 77:10645-10650.
58. Bukovsky AA, Dorfman T, Weimann A, Göttlinger HG (1997) Nef association with human immunodeficiency virus type 1 virions and cleavage by the viral protease. J Virol 71:1013-1018.
59. Welker R, Harris M, Cardel B, Kräusslich HG (1998) Virion incorporation of human immunodeficiency virus type 1 Nef is mediated by a bipartite membrane-targeting signal: Analysis of its role in enhancement of viral infectivity. J Virol 72:8833-8840.
60. Wang JK, Kiyokawa E, Verdin E, Trono D (2000) The Nef protein of HIV-1 associates with rafts and primes T cells for activation. Proc Natl Acad Sci USA 97:394-399.
61. Zheng YH, Plemenitas A, Fielding CJ, Peterlin BM (2003) Nef increases the synthesis of and transports cholesterol to lipid rafts and HIV-1 progeny virions. Proc Natl Acad Sci USA 100:8460-8465.
62. Zheng YH, Plemenitas A, Linnemann T, Fackler OT, Peterlin BM (2001) Nef increases infectivity of HIV via lipid rafts. Curr Biol 11:875-879.
63. Arold S, et al. (1997) The crystal structure of HIV-1 Nef protein bound to the Fyn kinase SH3 domain suggests a role for this complex in altered T cell receptor signaling. Structure 5:1361-1372.
64. Low A, et al. (2007) Mutation in the glycosylated gag protein of murine leukemia virus results in reduced in vivo infectivity and a novel defect in viral budding or release. J Virol 81:3685-3692.
65. Colicelli J, Goff SP (1988) Sequence and spacing requirements of a retrovirus integration site. J Mol Biol 199:47-59.
66. Pizzato M, Popova E, Göttlinger HG (2008) Nef can enhance the infectivity of receptor-pseudotyped human immunodeficiency virus type 1 particles. J Virol 82: 10811-10819.
67. Cosset FL, et al. (1995) Retroviral retargeting by envelopes expressing an N-terminal binding domain. J Virol 69:6314-6322.
68. Naldini L, et al. (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263-267.